CN104159606A - 含有hpv l2的免疫原性vlp及相关组合物和方法 - Google Patents

含有hpv l2的免疫原性vlp及相关组合物和方法 Download PDF

Info

Publication number
CN104159606A
CN104159606A CN201380012267.6A CN201380012267A CN104159606A CN 104159606 A CN104159606 A CN 104159606A CN 201380012267 A CN201380012267 A CN 201380012267A CN 104159606 A CN104159606 A CN 104159606A
Authority
CN
China
Prior art keywords
hpv
compositions
peptide
vlps
coat protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380012267.6A
Other languages
English (en)
Chinese (zh)
Inventor
B.查克利安
D.皮博迪
E.图姆班
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNM Rainforest Innovations
Original Assignee
STC UNM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STC UNM filed Critical STC UNM
Publication of CN104159606A publication Critical patent/CN104159606A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380012267.6A 2012-01-12 2013-01-10 含有hpv l2的免疫原性vlp及相关组合物和方法 Pending CN104159606A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261585839P 2012-01-12 2012-01-12
US61/585,839 2012-01-12
PCT/US2013/020960 WO2013106525A1 (en) 2012-01-12 2013-01-10 Immunogenic hpv l2-containing vlps and related compositions and methods

Publications (1)

Publication Number Publication Date
CN104159606A true CN104159606A (zh) 2014-11-19

Family

ID=48781889

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380012267.6A Pending CN104159606A (zh) 2012-01-12 2013-01-10 含有hpv l2的免疫原性vlp及相关组合物和方法

Country Status (8)

Country Link
EP (1) EP2802349B1 (enExample)
JP (1) JP6185932B2 (enExample)
CN (1) CN104159606A (enExample)
AU (1) AU2013207962B2 (enExample)
BR (1) BR112014017242A8 (enExample)
CA (1) CA2861021A1 (enExample)
HK (1) HK1203837A1 (enExample)
WO (1) WO2013106525A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549976B1 (en) 2012-11-16 2017-01-24 Stc.Unm Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
BR112016006344A2 (pt) 2013-09-12 2018-01-09 Leidos Inc vacina contra a malária, composição e métodos
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2017136400A1 (en) * 2016-02-02 2017-08-10 Stc. Unm Vlp-based vaccines for targeting staphylococcus aureus secreted virulence factors
CA3023788A1 (fr) * 2016-05-13 2017-11-16 Flash Therapeutics Particule virale pour le transfert d'arns, notamment dans les cellules impliquees dans la reponse immune
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
CA3076631A1 (en) * 2017-09-29 2019-04-04 Deutsches Krebsforschungszentrum Cutaneous papilloma virus vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136736A1 (en) * 1991-06-26 2002-09-26 Cancer Research Campaign Technology Limited Papillomavirus L2 protein
WO2006027300A2 (en) * 2004-08-04 2006-03-16 Cytos Biotechnology Ag Carrier conjugates of gnrh-peptides
WO2011100234A2 (en) * 2010-02-09 2011-08-18 Stc.Unm Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136736A1 (en) * 1991-06-26 2002-09-26 Cancer Research Campaign Technology Limited Papillomavirus L2 protein
WO2006027300A2 (en) * 2004-08-04 2006-03-16 Cytos Biotechnology Ag Carrier conjugates of gnrh-peptides
WO2011100234A2 (en) * 2010-02-09 2011-08-18 Stc.Unm Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DICO VAN MEERTEN等: "Peptide display on live MS2 phage: restrictions at the RNA genome level", 《JOURNAL OF GENERAL VIROLOGY》 *

Also Published As

Publication number Publication date
AU2013207962A1 (en) 2014-08-07
BR112014017242A8 (pt) 2017-07-04
EP2802349A1 (en) 2014-11-19
WO2013106525A1 (en) 2013-07-18
EP2802349B1 (en) 2017-12-06
HK1203837A1 (en) 2015-11-06
CA2861021A1 (en) 2013-07-18
JP6185932B2 (ja) 2017-08-23
EP2802349A4 (en) 2015-08-26
JP2015504897A (ja) 2015-02-16
BR112014017242A2 (pt) 2017-06-13
AU2013207962B2 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
AU2013207962B2 (en) Immunogenic HPV L2-containing VLPs and related compositions and methods
AU2021232660B2 (en) HPV vaccines
Tumban et al. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2
Naskalska et al. Virus like particles as immunogens and universal nanocarriers
AU2004290032B2 (en) Optimized expression of HPV 58 L1 in yeast
AU2004224335B2 (en) Optimized expression of HPV 31 L1 in yeast
HK1244695A1 (zh) Hpv颗粒及其用途
SG177269A1 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
US9884107B2 (en) Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
CN101314047A (zh) 治疗病毒感染的方法及其药物
Motevalli et al. Supercharged green fluorescent protein delivers HPV16E7 DNA and protein into mammalian cells in vitro and in vivo
US20170096456A1 (en) Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods
JP6863966B2 (ja) 標的ポリペプチドを提示するためのポリペプチド担体及びその使用
US9717783B2 (en) Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
US8778351B2 (en) Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2016026401A1 (zh) 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
CN103667319B (zh) 抗人乳头瘤病毒的三价疫苗及其制法和用途
CN101115766B (zh) 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1
CN110382518B (zh) 用于血清型a型口蹄疫病毒的嵌合疫苗
WO2004062584A2 (en) Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
Shokri et al. Designing of DNA vaccine based on a secretory form of major capsid protein of human papillomavirus type 18
Tornesello et al. Virus‑like particles as preventive and therapeutic cancer vac‑cines. Vaccines. 2022; 10: 227
Cui et al. Immunogenicity and protective efficacy of DHBV DNA vaccines expressing envelope and capsid fusion proteins in ducks delivered by attenuated Salmonella typhimurium
JP6916115B2 (ja) ＨＰＶＬ２ペプチド／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症用ワクチン
CA2996497C (en) Polypeptide carrier for presenting target polypeptide and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203837

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141119

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1203837

Country of ref document: HK